Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer - The ASCO Post
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer The ASCO Post
Endometriosis-Associated Ovarian Carcinosarcoma Featuring Well-Differentiated Adenocarcinoma and Fetal Rhabdomyoma-Like Mesenchymal Components: An Unusual Case Report-With Molecular Analysis.
Ovarian carcinosarcoma typically comprises high-grade carcinoma and sarcoma components. We report a case of a woman in her 40s with endometriosis-associated ovarian carcinosarcoma exhibiting an unusual presentation of well-differentiated adenocarcinoma …
Epigenetic Compound Library Screen Identifies Ibrutinib as an Inhibitor of Ovarian Clear Cell Carcinoma Viability.
Ovarian clear cell carcinoma (OCCC) is an endometriosis-associated ovarian cancer subtype. Somatic mutations in OCCC are reported in ARID1A, PIK3CA, and the TERT promoter (TERTp), as well as less commonly …
Endometriosis and Endometrial Cancer-Association Between Biological Mechanisms and Its Clinical Implications.
Endometriosis and endometrial cancer are distinct gynecological conditions that share overlapping biological mechanisms with implications for clinical management. Endometriosis is a chronic, benign disorder characterized by the ectopic implantation of …